A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris

Last updated: December 29, 2025
Sponsor: Pfizer
Overall Status: Completed

Phase

1

Condition

Acne

Rash

Scalp Disorders

Treatment

PF-07905428

Placebo

Clinical Study ID

NCT06671834
C5441001
  • Ages 18-40
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07905428) for the potential treatment of acne vulgaris.

This study is seeking participants who:

  • Are male or female between the ages of 18 and 40

  • Are generally healthy

  • Are diagnosed with moderate to severe acne vulgaris (Cohort 4 only)

The study medicine will be applied every day on the participant's face and/or back for 14 days (Cohorts 1 and 2) or for 28 days (Cohort 3 and 4).

The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help the investigators determine if the study medicine is safe and effective.

Participants will take part in this study for approximately 2 months. During this time, they will have 17 study visits (Cohorts 1 and 2) or 31 study visits (Cohorts 3 and 4) at the study clinic. The study team will also call participants once at the end of the study over the phone.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants who are overtly healthy as determined by medical evaluation.

  • Only for participants who are enrolling with acne vulgaris: diagnosis of acnevulgaris for 3 months or greater

  • For participants enrolling in Cohort 1-3 with acne vulgaris (optional): mild tomoderate facial acne vulgaris

  • For participants enrolling in Cohort 4 with acne vulgaris: moderate to severe facialacne vulgaris

Exclusion

Exclusion Criteria:

  • Participants with very severe acne

  • Participants with autoinflammatory syndromes

  • Evidence or history of clinically significant hematological, renal, endocrine,pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, orallergic disease

  • History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitisC.

  • Participants with clinically significant laboratory abnormalities

Study Design

Total Participants: 52
Treatment Group(s): 2
Primary Treatment: PF-07905428
Phase: 1
Study Start date:
November 22, 2024
Estimated Completion Date:
December 04, 2025

Connect with a study center

  • InnovaDerm

    Montreal, Quebec
    Canada

    Site Not Available

  • Innovaderm Research Inc.

    Montréal, Quebec H2X 2V1
    Canada

    Site Not Available

  • Innovaderm Research Inc.

    Montreal 6077243, Quebec 6115047 H2X 2V1
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.